pf-3512676 and Lymphoma--Mantle-Cell

Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission after immunochemotherapy, were vaccinated with irradiated, CpG-activated tumor cells. Subsequently, vaccine-primed lymphocytes were collected and reinfused after a standard autologous stem cell transplantation (ASCT). The primary endpoint was detection of minimal residual disease (MRD) within 1 yr after ASCT at the previously validated threshold of ≥1 malignant cell per 10,000 leukocyte equivalents. Of 45 evaluable patients, 40 (89%) were found to be MRD negative, and the MRD-positive patients experienced early subsequent relapse. The vaccination induced antitumor CD8 T cell immune responses in 40% of patients, and these were associated with favorable clinical outcomes. Patients with high tumor PD-L1 expression after in vitro exposure to CpG had inferior outcomes. Vaccination with CpG-stimulated autologous tumor cells followed by the adoptive transfer of vaccine-primed lymphocytes after ASCT is feasible and safe.

Topics: Adult; Aged; B7-H1 Antigen; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Endpoint Determination; Female; Humans; Immunity; Immunologic Memory; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm, Residual; Oligodeoxyribonucleotides; T-Lymphocytes; Transplantation, Autologous; Treatment Outcome